gsk1120212
Micropapillary Serous Carcinoma
National Cancer Institute (NCI)Phase 2/3Dormant
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Micropapillary Serous Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Letrozole Gynecologic Oncology Group | Phase 2/3 | BB |
Hycamtin National Cancer Institute (NCI) | Phase 2/3 | B |
Inno-206 National Cancer Institute (NCI) | Phase 2/3 | B |
TAMOXIFEN National Cancer Institute (NCI) | Phase 2/3 | B |
azd6244 National Cancer Institute (NCI) | Phase 2 | B |
Pembrolizumab North Eastern German Society of Gynaecological Oncology | Phase 2 | CCC |
Ribociclib Gynecologic Oncology Group | Phase 2 | CCC |
Same molecule, other indications
gsk1120212 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →